<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00137605</url>
  </required_header>
  <id_info>
    <org_study_id>CTN 147</org_study_id>
    <secondary_id>Control # 078760</secondary_id>
    <secondary_id>File # 9427-C1574-34C</secondary_id>
    <nct_id>NCT00137605</nct_id>
  </id_info>
  <brief_title>Early Versus Delayed Pneumococcal Vaccination in HIV</brief_title>
  <official_title>A Pilot Study Assessing the Efficacy of Pneumococcal Vaccine in HIV Patients: Delayed Versus Immediate Immunization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CIHR Canadian HIV Trials Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CIHR Canadian HIV Trials Network</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether people who are HIV-positive respond better
      to a vaccine for pneumonia-related disease when they are immunized immediately, or when
      immunization is delayed until the immune system has improved to a certain level. The study
      will also compare the effectiveness of polysaccharide and heptavalent vaccines.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicentre, randomized controlled trial using a two factorial design. Eighty patients will
      be randomly assigned to receive either Pneumovax (or Pneumo23 according to standard use at
      site) or heptavalent pneumococcal conjugate vaccine (Prevnar) prior to reconstitution of the
      immune system or will have immunization delayed until their CD4 count is greater than 200
      cells/mm3 after the introduction of antiretroviral therapy. Randomization will be stratified
      by study centre. Variable block sizes will be used to try to prevent study personnel from
      guessing the next allocation. Random allocation lists will be generated by computer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of serotypes to which a response is found</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>A response is defined as a doubling in antibody titer at 1 month compared to baseline.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody response at 6 months and one year</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in viral load 3 months post immunization</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall incidence of invasive pneumococcal disease</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of invasive pneumococcal disease between vaccines</measure>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>Pneumovax/immediate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pneumovax/delayed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Prevnar/immediate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Prevnar/delayed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumovax</intervention_name>
    <arm_group_label>Pneumovax/immediate</arm_group_label>
    <arm_group_label>Pneumovax/delayed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevnar</intervention_name>
    <arm_group_label>Prevnar/immediate</arm_group_label>
    <arm_group_label>Prevnar/delayed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-positive

          -  Between 18 and 65 years of age

          -  Have a CD4 cell count below 200 cells/mm3

          -  Willing to begin/change antiretroviral therapy

          -  Willing and able to provide informed consent

        Exclusion Criteria:

          -  Pregnant or breastfeeding

          -  Have had previous pneumococcal vaccination

          -  Have had occurrence of pneumococcal infection (brain, blood or lung infections) in
             past 5 years

          -  Have hypersensitivity to components of either vaccine

          -  Have acute feverish illness at the time of vaccination

          -  Have had splenectomy (removal of the spleen)

          -  Have received treatment with IVIG within the last 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Schlech, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Victoria General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Arts Health Research Group</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 1T2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Downtown IDC</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Boniface General Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moncton Hospital</name>
      <address>
        <city>Windsor</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Victoria General</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Hospital</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Chest/Royal-Victoria</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Laval</name>
      <address>
        <city>Ste-Foy</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Slayter KL, Singer J, Lee TC, Kayhty H, Schlech WF. Immunization against pneumococcal disease in HIV-infected patients: conjugate versus polysaccharide vaccine before or after reconstitution of the immune system (CTN-147). Int J STD AIDS. 2013 Mar;24(3):227-31. doi: 10.1177/0956462412472450. Epub 2013 May 6.</citation>
    <PMID>23535358</PMID>
  </results_reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2005</study_first_submitted>
  <study_first_submitted_qc>August 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2005</study_first_posted>
  <last_update_submitted>February 11, 2014</last_update_submitted>
  <last_update_submitted_qc>February 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2014</last_update_posted>
  <keyword>HIV</keyword>
  <keyword>HIV Infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

